← Back to KLRS

Kalaris Therapeutics, Inc. - Common Stock financial statements

Annual and standalone quarterly facts filed by the company with the SEC. Monetary values are shown in USD millions; per-share values use USD.

Filed statements

USD; millions except EPSJun 2026Filed 11/08/2026Mar 2026Filed 11/08/2026Sep 2025Filed 12/11/2025Jun 2025Filed 11/08/2026Mar 2025Filed 11/08/2026Sep 2024Filed 12/11/2025Jun 2024Filed 12/11/2025Mar 2024Filed 12/11/2025
−$12−$11−$12−$11−$10−$38−$5.7−$3.4
−$0.48−$0.46−$0.64−$0.61−$2.52−$28.16−$4.26−$2.60
242419194.1

Trend

Net income

Source: SEC EDGAR Company Facts. Values are normalized from issuer-filed US GAAP or IFRS XBRL facts. Missing cells stay missing; cumulative interim cash flows are not converted into estimated quarters.